BioPharma Services has been Acquired by HEALWELL AI to Significantly Enhance Clinical Research Capabilities
Toronto, ON, June 13 - BioPharma Services is thrilled to announce that HEALWELL AI signed a share purchase agreement with Think Research on June 13, 2024, to acquire BioPharma Services. HEALWELL AI, with WELL Health Technologies Corp. (TSX: WELL) as its largest...
BioPharma Services Awarded First-in-Human Study Evaluating for Gene Therapy Pre-treatment
Toronto, Canada, May 7, 2024 - BioPharma Services, a leading contract research organization specializing in early clinical trials, is pleased to announce that it has been awarded a groundbreaking First-in-Human (FIH) study. This milestone follows a significant...
BioPharma Services Completes Successful Inspection by the World Health Organization (WHO)
[TORONTO, July 17, 2023] — BioPharma Services, a leading Clinical Research Organization (CRO) globally renowned for advancing healthcare through clinical studies, recently completed a comprehensive inspection conducted by the World Health Organization (WHO) and Health...
BioPharma Services Bioanalytical Laboratory passes FDA inspection with flying colours
Following the recent inspection of the clinical site in St. Louis, Missouri (and previous to that, the Toronto clinic site in May 2022), FDA Inspectors came on site to inspect the BioPharma Services’ bioanalytical laboratory in Toronto, Canada. During the week of...
BioPharma Services Secures Successful FDA Inspection of St. Louis Clinical Facility
BioPharma Services is pleased to share that our US clinical site located near St. Louis, Missouri was the subject of an unannounced FDA inspection from October 4-6, 2022. Though BioPharma has a long successful FDA regulatory history in the US at the previous Columbia,...
BioPharma Services announces successful completion of Austrian Regulatory Agency (AGES) Audit
BioPharma Services Inc. is happy to report the successful completion of another regulatory industry audit. During the week of September 12, 2022, BioPharma was host to a multi-agency inspection. Leading the inspection were inspectors from the Austrian Agency for...
New BioPharma Contracts Signed During Q3 2022 Valued at $12.8 Million
Revenue recognition commencing in September to October timeframe. Average length of each program is approximately 12 months. TORONTO, ON, March 29, 2022 – Think Research Corporation (TSXV:THNK) (“Think” or the “Company”), a healthcare technology company focused on...
BioPharma Services Achieves Another Successful FDA Inspection Result
TORONTO, ON - June 16, 2022 - Think Research Corporation (TSXV:THNK) (OTCQB: THKKF) (“Think” or the “Company”), a company focused on transforming healthcare through digital health software solutions, is pleased to announce its subsidiary, BioPharma Services Inc.,...
BioPharma Services Receives 2022 Biotechnology Award from GHP
TORONTO, ON, April 29, 2022 – Slated for being a Leading Provider of Pharma Product of Clinical Trial Services in 2022, BioPharma Services Inc. is happy to announce its acceptance of the Biotechnology Award for this year. Presented by Global Health & Pharma...
BioPharma Services Receives Pharma Tech Outlook Top 10 CRO’s of 2022 Award
TORONTO, ON, April 28, 2022 – BioPharma Services Inc. is delighted to announce the acceptance of the Pharma Tech Outlook Top CRO's of 2022 award. Pharma Tech Outlook is a print and digital magazine that provides a knowledge network for scaling pharma technology...
Schedule a Discovery
Call Today
Complete the form to schedule a Discovery Call with one of our medical experts to learn how BioPharma Services can be your trusted clinical trial partner.